WOLVES HAND Co., Ltd.

Business Details

A single-segment company centered on Animal Hospital Operations, with expansion into Pet Salon Operations, Animal Hospital Software "Wantaro," Veterinary Medical Education Seminar "VMN," Manufacture and Sale of Medical Machinery and Equipment (Asuka Medical), and Healthcare and Environment-Related Products (Cartec) utilizing photocatalyst technology. The company operates a dominant network of center hospitals (secondary care) and satellite hospitals (primary care), providing seamless service from routine care to advanced medical treatment. It promotes a "Group Value Creation Spiral" in which medicine, technology, and data cyclically enhance value.

Recent Overview

Cumulative Q3 revenue up 13.6% and operating income up 43.6%, marking substantial profit growth, with business scope expanded through the consolidation of three new companies

For the cumulative nine months of Q3 FY2026 (ending June 2026) (July 2025 to March 2026), revenue increased significantly to ¥4,318 million (up 13.6% year on year), operating income rose to ¥674 million (up 43.6% year on year), and net income attributable to owners of parent rose to ¥597 million (up 98.5% year on year), marking substantial growth in both revenue and profit. In addition to organic growth at existing hospitals, the scope of consolidation expanded through the subsidiarization of Asuka Medical (October 2025) and Co., Ltd. See (November 2025), and the business transfer of the photocatalyst business by Cartec Co., Ltd. (January 2026). Extraordinary income included a gain on bargain purchase of ¥154 million and a gain on step acquisition of ¥12 million. In December 2025, the refinancing of pre-IPO LBO borrowings was completed, significantly reducing the current portion of long-term borrowings due within one year from ¥1,154 million to ¥449 million. The equity ratio improved from 44.9% to 51.8%. There is no change to the full-year earnings forecast (revenue of ¥6,150 million and operating income of ¥1,100 million).

Key Products

Growth Drivers

• Organic growth at existing hospitals (profitability improvement measures such as review of treatment pricing, optimal staff allocation, and cost synergies from group management)
• Expansion of locations and business areas through M&A (accelerated expansion into adjacent fields through Asuka Medical, Co., Ltd. See, the Cartec business transfer, etc.)
• Continued expansion of demand for animal medical care, driven by the increasing treatment of pets as family members, pet aging, and rising health consciousness
• Strengthening of coordination between primary and secondary care within the group through the dominant network of center hospitals and satellite hospitals
• Improved financial soundness and increased capacity for growth investment following the completion of the pre-IPO LBO refinancing (December 2025)
• Promotion of the "Group Value Creation Spiral" through the coordination of medical equipment (Asuka Medical), photocatalyst technology (Cartec), and AI, digital, and R&D domains

Risks

• Chronic shortage of veterinarians and intensifying recruitment competition (constrained by the bottleneck of university veterinary medicine department capacity)
• Risk of temporary cost increases associated with M&A and prolonged PMI (post-merger integration) (goodwill balance of ¥1,805 million as of end of March 2026)
• Risk from outstanding LBO- and M&A-related borrowings and rising interest rates (long-term borrowings of ¥1,637 million plus short-term borrowings of ¥100 million as of end of March 2026)
• Rising personnel and operating costs due to soaring raw material prices and inflation (external environment uncertainty including U.S. tariff policy and Middle East conditions)
• PMI risk related to the integration and monetization of the three newly consolidated companies (Asuka Medical, Co., Ltd. See, and Cartec)
• Risk of decline in revenue per veterinarian (temporary productivity decline associated with increased new graduate hiring)